ICDD - Innovative Concepts in Drug Development

ICDD - Innovative Concepts in Drug Development is a France-based biotechnology company founded in 2007. The company specializes in creating diagnostic products and services aimed at advancing the development of safe and effective drugs and personalized medicine to improve patient care.

ICDD's focus lies in predictive toxicology, drug efficacy, and diagnostics for CNS diseases, particularly neurodegeneration. The company employs proprietary technologies and innovative in vitro models to assist clients and partners in selecting the most efficient active compounds through fee for service or industrial partnership contracts.

ICDD's team of scientists, renowned for their expertise in mitochondrial function, dynamical system biology, and proteomics, operates screening models using cellular signatures for neurodegeneration in diseases such as Huntington’s and Alzheimer’s. Their services are instrumental in anticipating drug-induced adverse reactions and ensuring the proper selection of mitochondria-targeting agents in various diseases, including cancer, cardiovascular, metabolic, and CNS diseases.

The company has also devised models to utilize its unique technologies in assisting the cosmetic industry in testing the safety of their products. Additionally, ICDD substantiates commercial claims for anti-aging, anti-oxidation, sun protection, energizing, and firmness. ICDD secured a €800.00K Seed Round investment from Paca Investissement on 16 July 2012.